These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 16412833

  • 21. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 22. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
    Nazdik MK, Taheri M, Sajjadi E, Arsang-Jang S, Koohpar ZK, Inoko H, Sayad A.
    Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
    [Abstract] [Full Text] [Related]

  • 23. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.
    Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M.
    Mult Scler; 2005 Aug; 11(4):441-6. PubMed ID: 16042227
    [Abstract] [Full Text] [Related]

  • 24. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis.
    Yılmaz Ü, Gücüyener K, Atak A, Aral A, Gürkaş E, Demir E, Serdaroğlu A.
    Pediatr Neurol; 2012 Sep; 47(3):171-6. PubMed ID: 22883281
    [Abstract] [Full Text] [Related]

  • 25. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 26. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
    Waubant E, Gee L, Miller K, Stabler G, Goodkin D.
    J Interferon Cytokine Res; 2001 Mar 26; 21(3):181-5. PubMed ID: 11331041
    [Abstract] [Full Text] [Related]

  • 27. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar 26; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 28. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 26; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 29. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P.
    Nephrol Dial Transplant; 2007 Apr 26; 22(4):1115-22. PubMed ID: 17205957
    [Abstract] [Full Text] [Related]

  • 30. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes.
    Kouwenhoven M, Ozenci V, Gomes A, Yarilin D, Giedraitis V, Press R, Link H.
    J Autoimmun; 2001 Jun 26; 16(4):463-70. PubMed ID: 11437495
    [Abstract] [Full Text] [Related]

  • 31. [Changes of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the bronchoalveolar lavage fluid and the serum of patients with idiopathic pulmonary fibrosis].
    Wei LQ, Li ZH, Kang J, Hou XM, Yu RJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun 26; 29(6):399-402. PubMed ID: 17045024
    [Abstract] [Full Text] [Related]

  • 32. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T, Matsuda T, Suzuki Y, Ueda Y, Koide H.
    ASAIO J; 2003 Jun 26; 49(4):430-4. PubMed ID: 12918586
    [Abstract] [Full Text] [Related]

  • 33. Cerebrospinal fluid levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in subacute sclerosing panencephalitis.
    Ichiyama T, Matsushige T, Siba P, Suarkia D, Takasu T, Miki K, Furukawa S.
    J Infect; 2008 May 26; 56(5):376-80. PubMed ID: 18395263
    [Abstract] [Full Text] [Related]

  • 34. Association of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-4 in cerebrospinal fluid with blood-brain barrier dysfunction in patients with eosinophilic meningitis caused by Angiostrongylus cantonensis.
    Tsai HC, Chung LY, Chen ER, Liu YC, Lee SS, Chen YS, Sy CL, Wann SR, Yen CM.
    Am J Trop Med Hyg; 2008 Jan 26; 78(1):20-7. PubMed ID: 18187780
    [Abstract] [Full Text] [Related]

  • 35. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM, Novaes AB, Meschiari CA, Souza SL, Palioto DB, Sorgi CA, Faccioli LH, Tanus-Santos JE, Gerlach RF.
    Clin Chim Acta; 2009 Nov 26; 409(1-2):117-22. PubMed ID: 19751716
    [Abstract] [Full Text] [Related]

  • 36. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Nov 26; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 37. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, Montella S, Buonavolontà L, Florio C, Postiglione L.
    Immunopharmacol Immunotoxicol; 2008 Nov 26; 30(4):1-9. PubMed ID: 18686100
    [Abstract] [Full Text] [Related]

  • 38. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE.
    Clin Biochem; 2009 Jul 26; 42(10-11):984-90. PubMed ID: 19358835
    [Abstract] [Full Text] [Related]

  • 39. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I, Paolino E, Granieri E, Dallocchio F.
    Mult Scler; 2006 Jun 26; 12(3):294-301. PubMed ID: 16764342
    [Abstract] [Full Text] [Related]

  • 40. Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study.
    Olafsdóttir IS, Janson C, Lind L, Hulthe J, Gunnbjörnsdóttir M, Sundström J.
    Respirology; 2010 Apr 26; 15(3):530-5. PubMed ID: 20337997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.